Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08PKI
|
||||
| Former ID |
DIB012872
|
||||
| Drug Name |
EV-077
|
||||
| Synonyms |
EV-077-3201; EV-077 series (diabetes), Evolva Biotech; EV-077-3201-2; EV-077-3201-2TBS; Thromboxane antagonist (cardiovascular/proteinuric renal disease), Evolva Holding; Thromboxane synthesis inhibitor (cardiovascular/ proteinuric renal disease), Evolva Holding; EV-0400 series (metabolic disease/diabetes), Evolva Biotech; PPAR-gamma agonists (metabolic disease/diabetes/proteinuric renal disease/cardiovascular), Evolva Biotech
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [1] | ||
| Company |
Evolva SA
|
||||
| Target and Pathway | |||||
| Target(s) | Thromboxane-A synthase | Target Info | Modulator | ||
| BioCyc Pathway | C20 prostanoid biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Platelet activation | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Phase 1 - Functionalization of compounds | |||||
| Eicosanoid Synthesis | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01551381) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects. U.S. National Institutes of Health. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.